Last reviewed · How we verify
Antibiotic A 41030B (teicoplanin aglycone)
Antibiotic A 41030B (generic name: teicoplanin aglycone) is a teicoplanin aglycone drug. It is currently FDA-approved.
There is limited information available on Antibiotic A 41030B, including its modality, which is listed as "Unknown" in ChEMBL.
At a glance
| Generic name | teicoplanin aglycone |
|---|---|
| Drug class | teicoplanin aglycone |
| Target | Cathepsin L1 |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antibiotic A 41030B CI brief — competitive landscape report
- Antibiotic A 41030B updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Antibiotic A 41030B
What is Antibiotic A 41030B?
Antibiotic A 41030B (teicoplanin aglycone) is a teicoplanin aglycone drug.
What is the generic name of Antibiotic A 41030B?
teicoplanin aglycone is the generic (nonproprietary) name of Antibiotic A 41030B.
What drug class is Antibiotic A 41030B in?
Antibiotic A 41030B belongs to the teicoplanin aglycone class. See all teicoplanin aglycone drugs at /class/teicoplanin-aglycone.
What development phase is Antibiotic A 41030B in?
Antibiotic A 41030B is FDA-approved (marketed).
What does Antibiotic A 41030B target?
Antibiotic A 41030B targets Cathepsin L1 and is a teicoplanin aglycone.
Related
- Drug class: All teicoplanin aglycone drugs
- Target: All drugs targeting Cathepsin L1
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Metabolic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing